Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;15(Suppl 1):S5-S11.
doi: 10.4103/2230-8210.83053.

Noninsulin pharmacological management of type 1 diabetes mellitus

Vishvas Garg  1
Affiliations

Noninsulin pharmacological management of type 1 diabetes mellitus

Vishvas Garg. Indian J Endocrinol Metab. 2011 Jul.

Abstract

The injectable nature and other shortcomings of insulin have stimulated interest in studying the noninsulin pharmacological therapies to manage type 1 diabetes mellitus (T1DM). The purpose of this study is to conduct a systematic literature review of noninsulin pharmacological therapies for the management of T1DM. For this, the following PubMed search was conducted: Diabetes Mellitus, Type 1/therapy"[Mesh]

Limits: Review Sort by: Publication Date. After applying various inclusion and exclusion criteria, a total of 63 studies were reviewed. Based on this review, noninsulin pharmacological therapies can be divided into following classes: (1) Insulin-sensitizing agents (biguanides and thiazolidinediones), (2) gastrointestinal nutrient absorption modulators (α-Glucosidase inhibitors and amylin), (3) immunotherapeutic agents, (4) incretin-based therapies, (5) recombinant human insulin-like growth factors, and (6) other promising therapeutics. Some of these are already used either as monotherapy or adjuvant to insulin, whereas, to manage T1DM, the benefits and risks of the others are still under evaluation. Nonetheless, insulin still remains the cornerstone to manage the T1DM.

Keywords: Amylin; biguanides; immunotherapeutic agents; incretin-based therapies; insulin-like growth factors; thiazolidinediones; type 1 diabetes mellitus; α-glucosidase inhibitors.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Roadmap for the PubMed literature search
See this image and copyright information in PMC

References

    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53. - PubMed
    1. Diabetes Fact Sheet. 2011. [Last Accessed on 2011 Jan 04]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
    1. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2011;34:S62–9. - PMC - PubMed
    1. Kalra S, Kalra B, Sharma A. Prevalence of type 1 diabetes mellitus in Karnal district, Haryana state, India. Diabetol Metab Syndr. 2010;2:14. - PMC - PubMed
    1. Asha BP, Murthy BN, Chellamariappan M, Gupte MD, Krishnaswami CV. Prevalence of known diabetes in Chennai City. J Assoc Physicians India. 2001;49:974–81. - PubMed